| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9305fc720f87097494d965f1b1310e24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 |
| filingDate |
2019-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c12e81fc70584b571478cee20158016b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_567e3e06e3f695bb6a9fcb6f511cc7db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4512ba0a98fa5b643c623ea943c3126
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ad0a80c1e60583e01669778c81b111e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d310b415f52bb2234ae5d37b65892540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc03c5bb8c399ed4809167bd66b9e890
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49d8e82e12f012abe198acbf8c3ff5e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc2cb7c2cc72f50883cf7d3e8e0c7785
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00dcda86cf72abc164d4146a44af91d4 |
| publicationDate |
2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200026104-A |
| titleOfInvention |
Human NADP-dependent steroid dehydrogenase-like (NSDHL) enzyme inhibitors and pharmaceutical composition for use in preventing or treating cancer or hypercholesterolemia containing the same as an active ingredient |
| abstract |
The nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase (NSDHL) inhibitor provided in one aspect of the present invention is not only usable as an anticancer agent capable of overcoming the resistance of an EGFR target anticancer agent, but also has an effect that can be used to treat hyperlipidemia. |
| priorityDate |
2018-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |